CN1431905A - 福美斯坦在治疗抵抗性乳腺癌中的用途 - Google Patents

福美斯坦在治疗抵抗性乳腺癌中的用途 Download PDF

Info

Publication number
CN1431905A
CN1431905A CN01810539A CN01810539A CN1431905A CN 1431905 A CN1431905 A CN 1431905A CN 01810539 A CN01810539 A CN 01810539A CN 01810539 A CN01810539 A CN 01810539A CN 1431905 A CN1431905 A CN 1431905A
Authority
CN
China
Prior art keywords
treatment
breast cancer
patients
formestane
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01810539A
Other languages
English (en)
Chinese (zh)
Inventor
B·图尔利曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1431905(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1431905A publication Critical patent/CN1431905A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN01810539A 2000-04-05 2001-04-02 福美斯坦在治疗抵抗性乳腺癌中的用途 Pending CN1431905A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
GB0008172.9 2000-04-05

Publications (1)

Publication Number Publication Date
CN1431905A true CN1431905A (zh) 2003-07-23

Family

ID=9889101

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01810539A Pending CN1431905A (zh) 2000-04-05 2001-04-02 福美斯坦在治疗抵抗性乳腺癌中的用途

Country Status (28)

Country Link
US (2) US20030158166A1 (https=)
EP (2) EP1272195B1 (https=)
JP (1) JP2003528919A (https=)
KR (1) KR100757764B1 (https=)
CN (1) CN1431905A (https=)
AT (1) ATE306270T1 (https=)
AU (2) AU4437201A (https=)
BR (1) BR0109789A (https=)
CA (1) CA2403608A1 (https=)
CH (1) CH1272195H1 (https=)
CZ (1) CZ303096B6 (https=)
DE (1) DE60113975T2 (https=)
DK (1) DK1272195T3 (https=)
EE (1) EE05026B1 (https=)
ES (1) ES2248300T3 (https=)
GB (1) GB0008172D0 (https=)
HU (1) HU230064B1 (https=)
IL (2) IL151932A0 (https=)
IS (1) IS2869B (https=)
MX (1) MXPA02009744A (https=)
NO (1) NO329949B1 (https=)
NZ (1) NZ539603A (https=)
PL (1) PL201175B1 (https=)
RU (1) RU2265438C2 (https=)
SK (1) SK287779B6 (https=)
UA (1) UA80388C2 (https=)
WO (1) WO2001074366A1 (https=)
ZA (1) ZA200207538B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648523A (zh) * 2011-05-09 2014-03-19 弗吉尼亚大学专利基金会 用于治疗癌症的组合物和方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
HUP0400115A3 (en) * 2001-07-07 2005-11-28 Astrazeneca Ab Pharmaceutical composition for the intramuscular administration of fulvestrant
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
JP5256042B2 (ja) * 2005-11-22 2013-08-07 インサイト・コーポレイション 癌の処置のための併用療法
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
ES2708302T3 (es) 2011-05-20 2019-04-09 Capital Business Y Gestion De Finanzas S L Composición farmacéutica
WO2015106094A1 (en) * 2014-01-10 2015-07-16 Atossa Genetics Inc. Transpapillary methods and compositions for diagnosing and treating breast conditions
US9421264B2 (en) * 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
IL304863B2 (en) 2017-09-11 2025-08-01 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
WO2021174195A2 (en) * 2020-02-29 2021-09-02 The University Of Vermon Use of thyromimetics for the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648523A (zh) * 2011-05-09 2014-03-19 弗吉尼亚大学专利基金会 用于治疗癌症的组合物和方法

Also Published As

Publication number Publication date
HU230064B1 (hu) 2015-06-29
EP1272195B1 (en) 2005-10-12
CZ20023309A3 (cs) 2003-02-12
NO20024735D0 (no) 2002-10-02
EE05026B1 (et) 2008-06-16
HUP0300339A2 (hu) 2003-06-28
JP2003528919A (ja) 2003-09-30
GB0008172D0 (en) 2000-05-24
NO329949B1 (no) 2011-01-31
AU2001244372B2 (en) 2006-02-16
DE60113975D1 (de) 2006-02-23
HUP0300339A3 (en) 2009-01-28
MXPA02009744A (es) 2004-02-26
WO2001074366A1 (en) 2001-10-11
KR20030007501A (ko) 2003-01-23
EP1586323A1 (en) 2005-10-19
NO20024735L (no) 2002-11-27
SK14292002A3 (sk) 2003-08-05
CZ303096B6 (cs) 2012-04-04
RU2265438C2 (ru) 2005-12-10
ATE306270T1 (de) 2005-10-15
EE200200574A (et) 2004-04-15
PL201175B1 (pl) 2009-03-31
CH1272195H1 (https=) 2019-10-15
NZ539603A (en) 2008-02-29
EP1272195A1 (en) 2003-01-08
UA80388C2 (en) 2007-09-25
IL151932A0 (en) 2003-04-10
US20110183949A1 (en) 2011-07-28
SK287779B6 (sk) 2011-09-05
DE60113975T2 (de) 2006-06-22
DK1272195T3 (da) 2006-01-16
AU4437201A (en) 2001-10-15
HK1051498A1 (en) 2003-08-08
KR100757764B1 (ko) 2007-09-12
ES2248300T3 (es) 2006-03-16
BR0109789A (pt) 2003-01-21
IS6576A (is) 2002-10-01
CA2403608A1 (en) 2001-10-11
PL357936A1 (en) 2004-08-09
US20030158166A1 (en) 2003-08-21
IL151932A (en) 2007-07-04
IS2869B (is) 2014-03-15
ZA200207538B (en) 2003-12-19

Similar Documents

Publication Publication Date Title
US20110183949A1 (en) Use of Fulvestrant in the Treatment of Resistant Breast Cancer
US10034860B2 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
LoRusso et al. A first-in-human phase 1 study of a novel selective androgen receptor modulator (SARM), RAD140, in ER+/HER2-metastatic breast cancer
US20070078114A1 (en) Combination therapy for alzheimer's disease and other diseases
AU2001244372A1 (en) Use of fulvestrant in the treatment of resistant breast cancer
CZ201235A3 (cs) Fulvestrant pro použití pro lécbu postmenopauzálních žen s pokrocilým karcinomem prsu
JP2009029823A (ja) アンドロゲン除去によって生じる骨粗鬆症の治療
US20220257552A1 (en) Methods of prescreening and treating breast cancers with selective androgen receptor modulators
EP4493185A1 (en) Treatment of breast cancer with amcenestrant
US20230172897A1 (en) Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents
HK1051498B (en) Use of fulvestrant in the treatment of resistant breast cancer
HK1081842A (en) Use of fulvestrant in the treatment of resistant breast cancer
CN101404988A (zh) 乳腺癌治疗方案
Albanell Mestres et al. Palbociclib rechallenge for hormone receptor-positive/HER-negative advanced breast cancer: findings from the phase II BioPER trial
Ma et al. The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
CN118804747A (zh) 用安森司群治疗乳腺癌
KR20260006644A (ko) 유방암 치료에 사용하기 위한 카피바서티브, cdk4/6 억제제 및 풀베스트란트의 조합
CN120035437A (zh) 用于治疗EGFR突变癌症的N-(1-((R)-1-丙烯酰基氮杂环庚烷-3-基)-7-氯-6-(((R)-四氢呋喃-3-基)氧基)-1H-苯并[d]咪唑-2-基)-2-甲基异烟酰胺(NX-019)
WO2020233579A1 (zh) 一种降低阿帕替尼临床毒性的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication